Eribulin (Havalen) is a prescription drug used in the treatment of cancer. It is marketed by Eisai Co. under the trade name Halaven . Havalen is approved the US FDA to treat patients with metastatic breast cancer who have received prior chemotherapy regimens for late-stage disease, including anthracycline- and taxane-based chemo therapies. The drug is credited to increase the life expectancy of the patients in the throes of the last stage of cancer. It is also being tested for use in a variety of other solid tumors including prostate cancer,sarcomam, non-small cell lung cancer. It is available in vial form of 0.88mg/2ml.